Literature DB >> 10933775

Antimicrobial susceptibility of 19 Australian corneal isolates of Acanthamoeba.

L Lim1, D J Coster, P R Badenoch.   

Abstract

PURPOSE: To determine the in vitro drug susceptibility of Australian corneal isolates of Acanthamoeba and to correlate the results with patient treatment and visual outcome.
METHODS: Acanthomoeba isolates were obtained from a reference laboratory Cyst suspensions were prepared from 19 strains and exposed to 10 antimicrobial agents for 7 days. The minimum drug concentrations required to inhibit excystation were determined. Inhibited cells were then plated out to determine minimum cysticidal concentrations.
RESULTS: Overall, propamidine proved to be the most active anti-Acanthamoeba agent tested. The disinfectant polyhexamethylene biguanide, either pure or in Baquacil, was also effective. Pentamidine, hexamidine, chlorhexidine and chloroxylenol had intermediate activity, while neomycin, amphotericin B and povidone-iodine had poor activity. There was no clear relationship between in vitro susceptibility and visual outcome.
CONCLUSIONS: Propamidine and polyhexamethylene biguanide drops are recommended as initial choices for the treatment of Acanthamoeba keratitis. The variability in the susceptibility to any one agent suggests that individual testing of isolates is necessary to identify the most appropriate treatment. A number of factors influence visual outcome in these cases; further studies are required to resolve the importance or otherwise of in vitro susceptibility.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933775     DOI: 10.1046/j.1442-9071.2000.00275.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  9 in total

1.  Acanthamoeba encephalitis: isolation of genotype T1 in mycobacterial liquid culture medium.

Authors:  Rula Azzam; Paul R Badenoch; Michelle J Francis; Charles Fernandez; Penelope J Adamson; Claire Dendle; Ian Woolley; Jenny Robson; Tony M Korman; Maryza Graham
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

2.  Development of a practical complete-kill assay to evaluate anti-Acanthamoeba drugs.

Authors:  Regis P Kowalski; Salwa Abdel Aziz; Eric G Romanowski; Robert M Q Shanks; Amy C Nau; Leela V Raju
Journal:  JAMA Ophthalmol       Date:  2013-11       Impact factor: 7.389

3.  Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates.

Authors:  Simon Kilvington; Reanne Hughes; James Byas; John Dart
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

5.  In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii.

Authors:  A Mattana; G Biancu; L Alberti; A Accardo; G Delogu; P L Fiori; P Cappuccinelli
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium.

Authors:  Kirti Megha; Megha Sharma; Chayan Sharma; Amit Gupta; Rakesh Sehgal; Sumeeta Khurana
Journal:  Eye (Lond)       Date:  2021-09-21       Impact factor: 4.456

7.  Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis.

Authors:  Rebecca A Kuennen; Reynell Harder Smith; Thomas F Mauger; Elson Craig
Journal:  Clin Ophthalmol       Date:  2010-10-05

8.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

9.  In Vitro Comparison of the Acanthamoeba Cysticidal Activity of Povidone Iodine, Natamycin, and Chlorhexidine.

Authors:  Travis K Redd; Maya Talbott; Vicky Cevallos; Prajna Lalitha; Gerami D Seitzman; Thomas M Lietman; Jeremy D Keenan
Journal:  Ophthalmol Sci       Date:  2021-05-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.